Loading...
•
Dec 31, 2025
Silence Therapeutics Q4 2025 Earnings Report
Silence Therapeutics Q4 2025 Earnings Report
Key Takeaways
Silence Therapeutics focused on clinical execution in 2025, notably accelerating the Phase 2 SANRECO trial for divesiran. While the company reported a significant decrease in annual collaboration revenue following the conclusion of the Hansoh partnership and reduced AstraZeneca revenue, it maintains a solid cash position of $85.1 million to fund its prioritized siRNA pipeline.
Topline results for the Phase 2 SANRECO trial of divesiran in polycythemia vera are now expected in Q3 2026, ahead of previous guidance.
AstraZeneca will not pursue further development of SLN312 beyond Phase 1; Silence will regain exclusive global rights to the asset.
Cash, cash equivalents, and short-term investments totaled $85.1 million as of December 31, 2025.
Annual collaboration revenue fell to $0.6 million from $43.3 million in the prior year, primarily due to the conclusion of the Hansoh collaboration.
Forward Guidance
The company is prioritizing the development of divesiran and its mRNAi GOLD™ platform programs with several clinical and preclinical milestones expected in 2026.
Positive Outlook
- Topline Phase 2 SANRECO results for divesiran expected in Q3 2026.
- Additional preclinical data for SLN365 (GPR146) expected in Q2 2026.
- Additional preclinical data for SLN098 (INHBE) expected in Q2 2026.
- Phase 1 data presentations for SLN312 planned for medical congresses in 2026.
- Regaining exclusive global rights to SLN312 provides new strategic development options.
Challenges Ahead
- AstraZeneca discontinued development of SLN312 after Phase 1.
- Significant reduction in collaboration revenue compared to the prior year.
- Ongoing search for a permanent Chief Executive Officer.
- History of net operating losses expected to continue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...